Arbutus Biopharma Corp
Fechado
4.34 0.46
Visão Geral
Variação de preço das ações
24h
Mín
4.25
Máximo
4.38
Rendimento | 173M 170M |
|---|---|
Vendas | 178M 179M |
P/E Médio do Setor | 5.398 49.888 |
EPS | 1.19 |
Margem de lucro | 94.735 |
Funcionários | 19 |
EBITDA | 177M 169M |
Próximos Ganhos | 5 de ago. de 2026 |
|---|
Capitalização de Mercado | 20M 885M |
|---|---|
Abertura anterior | 3.88 |
Fecho anterior | 4.34 |
Arbutus Biopharma Corp Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Arbutus Biopharma Corp Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
